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In the past few decades there has been a progressive understanding that epicutaneous sensitization with
protein antigen is an important sensitization route in patients with atopic dermatitis. A murine protein-
patch model has been established, and an abundance of data has been obtained from experiments using
this model. This review discusses the characteristics of epicutaneous sensitization with protein antigen,
the induced immune responses, the underlying mechanisms, and the therapeutic potential.
Copyright  2012, Taiwanese Dermatological Association.
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It was long considered very difﬁcult, if not impossible, for atopic
allergens to penetrate normal skin because the skin was consid-
ered to be impermeable to high-molecular-weight, hydrophilic
proteins.1 However, this notion has always been challenged by
clinical observations. Contact urticaria occurs a few minutes after
putting on latex gloves in a latex-sensitized patient.2 Protein
contact dermatitis, observed in butchers, can be reproduced using
meat proteins.3 Atopic patch tests to protein allergens are positive
(clinical dermatitis), even when carried out on normal skin
of atopic dermatitis (AD) patients.4 Moreover, proliferative
responses of memory T cell to allergens are preferentially detected
in cutaneous lymphocyte antigen+ T cells in AD patients, but not
asthma patients.5 The percentage of type 2 cytokine-producing
cells is remarkably increased among the cutaneous lymphocyte
antigen+ subset, whereas the percentage of type 1 cytokine-
producing cells is decreased.6 The last two studies suggest that
these cells were primed or reactivated in the cutaneous immune
system. In recent years, the demonstration that mutation in the
ﬁlaggrin gene is a predisposing factor for AD has convinced many
investigators that epicutaneous (EC) sensitization with protein
antigen (Ag) is one of the important routes of allergen sensitiza-
tion for AD.7y, National Taiwan University
ipei, Taiwan. Tel.: þ886 2
.
iwanese Dermatological AssociatioMethodology of murine models of EC sensitization with
protein Ag
Our laboratory developed a murine protein-patch model to study EC
sensitization with protein Ag approximately 20 years ago.8 In this
model, ovalbumin (OVA) solution is ﬁrst applied to a 1-cm2 gauze on
patches or discs in Finn chambers, which were applied to shaved
backswithout prior tape-stripping. The patcheswere renewed either
every day for 5 successive days or on Day 4. Our method emphasizes
mimicking physiologic conditions with repeated exposure, without
disruption of the skin barrier and without the use of adjuvants.
Subsequently, Spergel et al9 reported another EC sensitization model
in 1998. Spergel et al9 also used a l  l cm patch of sterile gauze
secured to the back skin, but with two modiﬁcations. First, they
performed tape-stripping before application of the patch to disrupt
the skin barrier. Second, one patch was placed for 1 week before
being removed. Twoweeks later, an identical patch was reapplied to
the same skin site. Thus, one mouse had a total of three 1-week
exposures to the patch separated by a 2-week interval. A number
of researchers have since used the protein-patch model to study EC
sensitization using different protein Ags, including allergens of
atopic diseases, rubber latex Ag, autoantigens, parasite Ags, super-
antigens, toxins, and hapten-conjugated immunoglobumins.10e16
The immune responses induced by EC sensitization with
protein Ag
After establishment of the murine protein-patch model, immune
responses induced by EC sensitization with protein Ag weren. Published by Elsevier Taiwan LLC. All rights reserved.
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induced a predominant T helper 2 (Th2) and a marginal Th1
response with high IgE production in mice.8 EC sensitization with
house dust mite Ag was also shown to elicit a Th2-dominant
cytokine response.10,17 Strid et al18 emphasized the importance of
the route of immunization by comparing EC with subcutaneous
immunization and showed that EC immunization with peanut
protein generates a predominant Th2 response, whereas subcuta-
neous immunization elicits a predominant Th1 response. For Th17
cells, He et al19 reported that EC sensitization with OVA induced
a remarkable Th17 response. In contrast, we demonstrated that EC
sensitization with OVA induced a modest increase in Th17
response.20 The discrepancy in the magnitude of the Th17 response
might be explained by the use of tape-stripping before EC sensiti-
zation because in addition to removing the skin barrier, tape-
stripping has been shown to induce epidermal inﬂammation,
which might promote Th17 development.21 EC sensitization with
protein Ag also generates regulatory T cells (Treg), which is
evidence that EC immunization with an autoantigen induces Treg
that prevents experimental allergic encephalomyelitis.22 EC
immunization also induces T cell receptor abþCD4þCD8þ double-
positive Treg that inhibit contact hypersensitivity and experi-
mental allergic encephalomyelitis.16,23 Recently, Th9, a new Th
lineage, has been deﬁned and we demonstrated that EC sensitiza-
tionwith OVA also induces a small number of Th9 cells.24 For CD8 T
cells, surprisingly, cross-priming with an soluble protein antigen
introduced epicutaneously generates cytotoxic T cell (Tc1), but not
Tc2 cells.25
Mechanisms of EC sensitization with protein Ag
The role of the skin barrier
Protein Ag sensitization via the EC route needs to ﬁrst overcome the
epidermal barrier. The barrier function of the skin has the following
three elements: the stratum corneum (air-liquid barrier); the tight
junction (liquid-liquid barrier); and the Langerhans cell (LC)
network (immunologic barrier).26 Skin barriers face harsh chal-
lenges in modern lifestyles with regular use of soap in bathing and
long-term exposure to air conditioned or heated environments.
This might account, in part, for the progressive increase in atopic
diseases in industrialized countries in the past few decades. For the
stratum corneum, ﬁlaggrin mutations have been repeatedly
demonstrated to be a predisposing factor for AD.7,27 An altered
stratum corneum barrier, enhanced allergen sensitization, and
spontaneous development of dermatitis have all been demon-
strated in ﬁlaggrin-deﬁcient mice.28,29 Filaggrin loss-of-function
mutations have further been shown to be associated with
enhanced IL-1 expression in the stratum corneum of patients with
AD and in ﬁlaggrin-deﬁcient mice.30 The contribution of a stratum
corneum deﬁciency to EC sensitization with protein Ag is further
supported by the clinical observation of an association of genes
controlling desquamation, such as serine protease inhibitor and
stratum corneum chymotryptic enzyme, with the development of
AD.31,32 For tight junctions, a polymorphism in the claudin-1 gene,
which is one of the major components of epidermal tight junctions,
was recently reported to be associated with AD.33 Interestingly,
cutaneous barrier perturbation can not only stimulate proin-
ﬂammatory cytokine production in the epidermis, but also induce
LC activation with the dendrites penetrating the tight junction
barrier and facilitating capture of Ag by LCs.21,34 Thus, disruption of
the skin barrier can enhance EC sensitization with protein Ag by
allowing Ag penetration, inducing inﬂammation, and triggering LC
activation. For the quality of induced immune responses under
a skin barrier deﬁciency, it appears that all of the Th1/Th2/Th17responses are increased and no polarization of Th1/Th2/Th17
responses occurs.35
The role of cytokines
The gene knockout mouse system has been used to investigate the
elements and the associated contributions in EC sensitization with
protein Ag. Because the predominant immune response induced by
EC is the Th2 response, it was ﬁrst hypothesized that Th2 cytokines,
especially interleukin (IL)-4, might be essential. However, Herrick
et al36,37 demonstrated that IL-13, but not IL-4 is necessary but not
simply sufﬁcient for epicutaneously-induced Th2 responses to
soluble protein antigen. He et al38 further showed an exaggerated
Th17 response after EC sensitization with OVA in IL-4/IL-13 double
knockout mice.Laouini et al39 also demonstrated that IL-10-
deﬁcient mice have a decreased Th2 and increased Th1 response
to EC sensitization, and suggested that dendritic cells (DCs) and T
cells participate in IL-10 skewing of the Th2 response. IL-21R-
deﬁcient mice have been shown to have impaired Th1 and Th2
responses after EC sensitization, which is likely to be due to
defective mobilization of skin DCs to draining lymph nodes.40 In
contrast, SMAD3-deﬁcient mice exhibit higher levels of OVA-
speciﬁc IgE, but not IgG2a after EC sensitization with OVA than
wild-type controls, implying that transforming growth factor
(TGF)-b-SMAD3 signaling has a suppressive effect on the induced
Th2 response.41 Recently, we demonstrated that IL-9 can promote
Th2 responses induced by EC sensitization with OVA.24Taken
together, the predominant Th2 response induced in EC sensitiza-
tionwith protein Ag is promoted by IL-13, IL-10, IL-21, and IL-9, but
suppressed by TGF-b.
The role of Toll-like receptor ligands and other innate elements
The effects of various Toll-like receptor TLR ligands on the Th
responses induced by EC sensitization with protein Ag have been
investigated. TLR2 is important for the Th1 response, but not the
Th2 response, because (interferon) IFN-g production (Th1
response) by splenocytes after restimulation and anti-OVA IgG2a
Ab levels are impaired in TLR2-deﬁcient mice, whereas the Th2
cytokine production and anti-OVA IgE Ab level are comparable to
wild-type controls.42 In contrast, the Th1 and Th2 responses
induced by EC sensitizationwith protein Ag is TLR4-independent.43
Ptak et al44 further showed that EC sensitization with protein
antigen in the presence of TLR4 ligand induced contrasuppressor
cells that can reverse skin-induced suppression of Th1-mediated
contact sensitivity.For CD8 T cells, topical co-administration of
TLR9 ligand with protein Ag promotes the generation of cytotoxic T
cells in EC sensitization, whereas ligands for TLR2, TLR3, or TLR4
have no effect.25,43,45Overall, the predominant Th2 response
induced in EC sensitization with protein Ag is TLR-independent;
however, TLR9 ligand can promote cross-priming in EC sensitiza-
tion to CD8 T cells.
Other mediators in innate immunity have been reported to
modulate the immune responses induced by EC sensitization with
protein Ag. Cyclooxygenase-2 suppresses the induced Th2
response, whereas agonizing prostaglandin D2 receptor (CRTH2)
has no effect on the induced immune responses as evidenced by the
observation that CRTH2-deﬁcient mice showed comparable
responses with wild-type mice.46,47 Macrophage migration inhib-
itory factor (MIF)-deﬁcient mice have decreased Th2 and increased
Treg production after EC sensitization when compared with wild-
type controls.48 Galectin-3 deﬁciency results in a decreased Th2
response and a Th1-polarized response.49 C3aR-deﬁcient mice
exhibit an exaggerated Th2 response, whereas C3-deﬁcient mice
have impaired Th1 and Th2 responses.50,51Moreover, skin
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in epicutaneous-immunized mice.52 Topical superantigen co-
exposure in EC sensitization with OVA results in an increase of
both Th1 and Th2 responses.53 We demonstrated that low-energy
visible light irradiation suppresses the strong Th2 response
induced in BALB/c mice, but enhances the weaker Th2 response in
C57BL/6 mice.54
The role of DC subsets
The roles various DC subsets play in EC sensitization with protein
Ag have been studied using Langerin-diphtheria toxin receptor
knock-in mice and Langerin-diphtheria toxin A transgenic mice. It
has been shown that LCs initiate EC sensitization with OVA and
induce Th2 immune responses via thymic stromal lymphopoietin
signaling.55 LCs are also critical for induced Th2 responses when
using exfoliative toxin as an antigen.15 In contrast, probably
because EC sensitization induces a Th2-predominant response and
there are still no langerin dermal DC-deﬁcient mice available, the
roles that langerinþ dermal DCs and langerin dermal DCs play in
inducing Th responses in EC sensitization remain obscure. With
respect to CD8 T cells, recent studies have demonstrated that
langerinþ dermal DCs have an essential role in cross-presentation
of EC sensitization and LCs are dispensable.56,57Elkhal et al58 re-
ported that mice with NKT cell deﬁciency have comparable OVA-
speciﬁc IgG1, IgG2a, and IgE levels after EC sensitization with
OVA, thus suggesting that CD1d-restricted NKT cells are not
required for EC sensitization. However, our experiments showed
that CD1d-KO mice have increased Th2 responses after EC sensi-
tization with OVA (unpublished data). The discrepancy might be
explained by different methodologies, especially with or without
prior tape-stripping.
The role of antigen characteristics
The same proteins typically behave as allergens across the human
population. It is still not clear which factors determine the aller-
genicity of proteins within the natural environment. The current
theory focuses on a common structural motif and enzymatic
properties.59 Many atopic allergens possess enzyme activities. It
has been shown that Der p1, the major allergen in house dust mite,
facilitates transepithelial allergen delivery by disruption of tight
junctions, with occludin serving as a functional target of peptidase
activity.60,61 The effects of natural allergens on DCs have been
investigated. The proteolytic activity of the major dust mite
allergen conditioned DCs to produce less IL-12, thus directing DCs
to induce Th2 development.62 Aqueous birch pollen enhances the
migratory capacity of DCs and prepare DCs for Th2 attraction by
modulating the expression of chemokines and chemokine recep-
tors.63 House dust mite extract stimulated a robust production of
cysteinyl leukotrienes from pulmonary DCs via dectin-2 recogni-
tion.64 Natural allergens also have effects on epithelial cells. Natural
allergens induce proinﬂammatory cytokines from respiratory
epithelial cells and delayed epidermal permeability barrier
recovery, both mediated by activation of PAR-2.65,66 Most impor-
tantly, Derp 2 has been shown to have structural and functional
homology with MD-2 (a protein associated with TLR4 on the cell
surface), facilitating signaling through direct interaction with the
TLR4 complex, and reconstituting LPS-driven TLR4 signaling in the
absence of MD-2.67 Thus, house dust mite extract has Th2 adjuvant
and tolerogenic activities in intranasal sensitization.68 Because EC
sensitization with protein Ag has been shown to be TLR-4-
independent, whether or not all or part of the above-mentioned
mechanisms operate in EC sensitization needs further investiga-
tion and remains largely unknown at present.Establishment of murine models of AD, asthma and food
allergy by EC sensitization with protein Ag
Spergel et al9 ﬁrst demonstrated that by thrice-repeating EC OVA
patch application, an AD-like cutaneous inﬂammation could be
induced. The cutaneous inﬂammation was characterized by inﬁl-
tration of T cells, eosinophils, and neutrophils, and by local expres-
sion of mRNA for IL-4, IL-5, and IFN-g. Later, by using IL-4, IL-5 and
IFN-g knockout mice, they showed that Th2 and Th1 cytokines play
important roles in AD-like dermatitis.69 Spergel et al9 also extended
the EC route as a sensitization method for asthma, showing a single
exposure of EC-sensitized mice to aerosolized OVA induced eosin-
ophils in the bronchoalveolar lavage ﬂuid and airway hypersensi-
tivity to intravenous methacholine. Later, He et al19 suggested that
Th17 cells play an important role in driving airway inﬂammation
after inhalation challenge. The investigation of underlying mecha-
nisms of the progression from AD to asthma revealed that thymic
stromal lymphopoietin overexpressed by skin keratinocytes is the
systemic driver of this bronchial hyper-responsiveness.70 Akei et al71
established an experimental allergic rhinitis model by showing
that EC aeroallergen exposure induces systemic Th2 immunity
that predisposes to allergic nasal responses via a STAT6-dependent
pathway. Akei et al72 also reported that EC antigen is a primer for
experimental eosinophilic exposure esophagitis in mice. For food
allergies, our group showed that food allergy (anaphylaxis) could be
induced by EC.73 It has also been shown that EC exposure to peanut
protein can prevent induction of oral tolerance and may even
modify existing tolerance to peanuts.74 Thus, at least in the murine
experimental system, primed T cells in EC sensitizationwith protein
Ag can trafﬁc to develop pathologic changes in other organ systems.
EC sensitization with protein Ag as a novel method of
allergen-speciﬁc immunotherapy
Because EC sensitization with protein Ag induces Th2 and Treg cells,
the effects on established immune responses or ongoing pathologic
conditions have been explored. In 2006, Strid et al75 ﬁrst reported
that EC immunization converts subsequent and established antigen-
speciﬁc Th1- -to Th2-type responses in mice. Subsequently, they
demonstrated that EC immunizationwith type II collagen inhibit the
onset and progression of murine chronic collagen-induced arthri-
tis.76Senti et al77ﬁrst developed EC immunotherapy in humans. By
applying four allergen-containing patches to the patient’s upper arm
at weekly intervals,they reported that patients receiving EC immu-
notherapy showed signiﬁcantly decreased scores in a nasal provo-
cation test in 2009. Later, a French company (DBV Technologies)
developed a new EC delivery system, called Viaskin, that could
promote diffusion of allergens toward skin without any skin prepa-
ration or adjuvant.78 DBV Technologies developed a new regimen to
apply the EC delivery system for 48 hours/week for eight times and
showed that in mice sensitized to the four allergens tested, EC
immunotherapy was as efﬁcient as subcutaneous immunother-
apy.78Dupont et al79reported that EC immunotherapy was safe, well
tolerated, and exhibited a clear trend toward clinical efﬁcacy for
childrenwith cow’s milk allergy. EC immunotherapy could also block
the allergic esophago-gastro-enteropathy induced by sustained oral
exposure to peanuts in sensitized mice.80 The underlying mecha-
nismsmight be that after protein Ag is applied repeatedlywith the EC
delivery system, speciﬁc local and systemic responses are down-
regulated in association with the induction of regulatory T cells.81
Conclusions and future perspectives
At present, we have learned that EC sensitizationwith protein Ag is
an important route for AD, which induces predominant Th2,
Figure 1 Summary of epicutaneous sensitization.
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modulating factors have been identiﬁed, including cytokines, T cell
receptor signaling, complement, and lipid mediators (summarized
in Figure 1). However, an understanding of the mechanisms of EC
sensitization with protein Ag is just beginning. Some basic ques-
tions remain. For example, why does EC sensitization with protein
and hapten induce such different responses? Why does EC sensi-
tization with protein Ag induce differential responses in human
atopy and nonatopy? EC sensitization with protein antigen and
with hapten are major routes for atopic dermatitis and allergic
contact dermatitis, respectively. Haptens are small chemicals that
penetrate skin easily and need to react covalently with carrier
proteins before being recognized as immunogens by the immune
system. Protein antigens are large hydrophilic molecules that
penetrate skin with difﬁculty. Thus, knowledge obtained from
murine contact hypersensitivity model and human allergic contact
dermatitis could not be applied to EC sensitization with protein
antigen directly. The clinical importance as well as its therapeutic
potential emphasizes the demand for EC sensitization with protein
Ag to be intensively investigated.References
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